New RT-PCR test designed for the qualitative detection of RNA from the Influenza A (Flu A), Influenza B (Flu B) and/or SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs from individuals suspected of respiratory infections by their healthcare provider.
Although the pneumonia is the principal illness associated, a few patients have developed severe pneumonia, pulmonary edema, acute respiratory distress syndrome, or multiple organ failure and death.
Centers of Disease Control and Prevention (CDC) believes that symptoms of SARS-CoV-2 may appear in as few as 2 days or as long as 14 days after exposure, being the most common fever or chills, cough, fatigue, anorexia, myalgia and dyspnea.
Viruses cause most of the viral infections of the lower respiratory tract. Influenza A and B are a major cause of morbidity and mortality throughout the world, presenting symptoms such as fever or feverish feeling, chills, cough, sore throat, stuffy and runny nose, myalgia, headache, and anorexia.
Diagnosis can be problematic, as a wide range of pathogens can cause acute respiratory infections presenting with similar clinical syndromes. Real-time PCR assays have been shown to be a sensitive and specific diagnostic tool for the detection of Influenza A, Influenza B and SARS-CoV-2 viruses.
Link to product information, here.
